Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of UV-B phototherapy in breast cancer cells
- PMID: 24138843
- PMCID: PMC4015769
- DOI: 10.1186/1476-4598-12-122
Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of UV-B phototherapy in breast cancer cells
Abstract
Background: The hypoxic environment of tumor region stimulated the up regulation of growth factors responsible for angiogenesis and tumor proliferation. Thus, targeting the tumor vasculature along with the proliferation by dual tyrosine kinase inhibitor may be the efficient way of treating advanced breast cancers, which can be further enhanced by combining with radiotherapy. However, the effectiveness of radiotherapy may be severely compromised by toxicities and tumor resistance due to radiation-induced adaptive response contributing to recurrence and metastases of breast cancer. The rational of using ZD6474 is to evaluate the feasibility and efficacy of combined VEGFR2 and EGFR targeting with concurrent targeted and localized UV-B phototherapy in vitro breast cancer cells with the anticipation to cure skin lesions infiltrated with breast cancer cells.
Materials and methods: Breast cancer cells were exposed to UV-B and ZD6474 and the cell viability, apoptosis, invasion and motility studies were conducted for the combinatorial effect. Graphs and statistical analyses were performed using Graph Pad Prism 5.0.
Results: ZD6474 and UV-B decreased cell viability in breast cancers in combinatorial manner without affecting the normal human mammary epithelial cells. ZD6474 inhibited cyclin E expression and induced p53 expression when combined with UV-B. It activated stress induced mitochondrial pathway by inducing translocation of bax and cytochrome-c. The combination of ZD6474 with UV-B vs. either agent alone also more potently down-regulated the anti-apoptotic bcl-2 protein, up-regulated pro-apoptotic signaling events involving expression of bax, activation of caspase-3 and caspase-7 proteins, and induced poly (ADP-ribose) polymerase resulting in apoptosis. ZD6474 combined with UV-B inhibited invasion of breast cancer cells in vitro as compared to either single agent, indicating a potential involvement of pro-angiogenic growth factors in regulating the altered expression and reorganization of cytoskeletal proteins in combinatorial treated breast cancer cells. Involvement of combination therapy in reducing the expression of matrix metalloprotease was also observed.
Conclusions: Collectively, our studies indicate that incorporating an anti-EGFR plus VEGFR strategy (ZD6474) with phototherapy (UV-B), an alternative approach to the ongoing conventional radiotherapy for the treatment of infiltrating metastatic breast cancer cells in the skin and for locally recurrence breast cancer than either approach alone.
Figures






Similar articles
-
ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells.J Cell Physiol. 2011 Feb;226(2):375-84. doi: 10.1002/jcp.22343. J Cell Physiol. 2011. PMID: 20665703
-
ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells.Cancer Biol Ther. 2010 Apr 15;9(8):592-603. doi: 10.4161/cbt.9.8.11103. Epub 2010 Apr 4. Cancer Biol Ther. 2010. PMID: 20139705
-
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.Clin Cancer Res. 2003 Apr;9(4):1546-56. Clin Cancer Res. 2003. PMID: 12684431
-
ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity.Br J Cancer. 2005 Jun;92 Suppl 1(Suppl 1):S6-13. doi: 10.1038/sj.bjc.6602603. Br J Cancer. 2005. PMID: 15928657 Free PMC article. Review.
-
ZD6474, a small molecule tyrosine kinase inhibitor, potentiates the anti-tumor and anti-metastasis effects of radiation for human nasopharyngeal carcinoma.Curr Cancer Drug Targets. 2010 Sep;10(6):611-22. doi: 10.2174/156800910791859506. Curr Cancer Drug Targets. 2010. PMID: 20491619 Review.
Cited by
-
Targeting Apoptotic Pathway of Cancer Cells with Phytochemicals and Plant-Based Nanomaterials.Biomolecules. 2023 Jan 18;13(2):194. doi: 10.3390/biom13020194. Biomolecules. 2023. PMID: 36830564 Free PMC article. Review.
-
Targeted Knockdown of Macrophage Migration Inhibitory Factor Enhances UVB Irradiation-Induced Apoptosis Via Increasing ROS Generation in Oral Squamous Cell Carcinoma.Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231163436. doi: 10.1177/15330338231163436. Technol Cancer Res Treat. 2023. PMID: 37272017 Free PMC article.
-
Targeting human epidermal growth factor receptor 2 enhances radiosensitivity and reduces the metastatic potential of Lewis lung carcinoma cells.Radiat Oncol. 2020 Mar 6;15(1):58. doi: 10.1186/s13014-020-01493-8. Radiat Oncol. 2020. PMID: 32143669 Free PMC article.
-
MEOX2 mediates cisplatin resistance in ovarian cancer via E2F target and DNA repair pathways.J Ovarian Res. 2025 Mar 21;18(1):58. doi: 10.1186/s13048-025-01641-2. J Ovarian Res. 2025. PMID: 40119426 Free PMC article.
-
Novel ZnO hollow-nanocarriers containing paclitaxel targeting folate-receptors in a malignant pH-microenvironment for effective monitoring and promoting breast tumor regression.Sci Rep. 2015 Jul 6;5:11760. doi: 10.1038/srep11760. Sci Rep. 2015. PMID: 26145450 Free PMC article.
References
-
- Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S. et al.Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;12:2087–2106. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous